Share This Article:

Gankyrin: A potential target for drug therapy against hepatocellular carcinoma

Abstract Full-Text HTML Download Download as PDF (Size:974KB) PP. 469-475
DOI: 10.4236/jbise.2012.58059    3,828 Downloads   6,177 Views   Citations

ABSTRACT

Hepatocellular Carcinoma is a primary malignant tumor of the liver and gankyrin is an oncoprotein over-expressed in hepatocellular carcinoma. It has been found that Gankyrin protein reduces the level of p53 protein by increasing its ubiquitylation and degradation, following a MDM-2 mediated pathway. Interaction of gankyrin with MDM2 enhances the ubiquitylation of p53. Independent study of this protein molecule revealed that it is identical to the p28 subunit of the 26S proteasome, having seven similar alpha helical ankyrin repeats. Gankyrin also binds to the Tumor Suppressor Protein (TSP) Retinoblastoma (RB), thereby accelerating its phosphorylation and proteasomal degradation. Blocking the expression of Gankyrin with MDM2 in cases of Hepatocellular Carcinoma (HCC) promoted apoptosis in cancer cells. Hence, Gankyrin can be used as a potential target for drug therapy against Hepatocellular Carcinoma.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Gandhi, S. , Puri, V. and Puri, S. (2012) Gankyrin: A potential target for drug therapy against hepatocellular carcinoma. Journal of Biomedical Science and Engineering, 5, 469-475. doi: 10.4236/jbise.2012.58059.

References

[1] erman J. J. (2004) Tumor taxanomy for the developmental classification of neoplasms. BMC Cancer, 4, 88-93. doi:10.1186/1471-2407-4-88.
[2] Thomas M. B. (2005) Hepatocellular Carcinoma: The need for progress. J Clin Oncol, 23, 2892-2899. doi:10.1200/JCO.2005.03.196.
[3] Quelle D.E., Zindy F., Ashmun R. A., and Sherr C. J. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83, 993–1000. doi:10.1016/0092-8674(95)90214-7.
[4] Iwakuma T. and Lozano G. (2003) MDM2, an introduction. Mol Cancer Res, 1, 993–1000. PMID:14707282 doi:10.1158/1541-7786
[5] Ieta K., Ojima E., Tanaka F., Nakamura Y., Haraguchi N., Mimori K., Inoue H., Kuwano H. and Mori M. (2007) Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int. J. Cancer, 121, 33–38. doi:10.1002/ijc.22605.
[6] Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., Mayer R.J., Arii S., and Fujita J. (2000) Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med, 6, 96-99. doi:10.1038/71600
[7] Manjasetty B. A., Quedenau C., Sievert V., Büssow C., Niesen F., Delbrück H. and Heinemann U. (2004) X-Ray structure of Human Gankyrin, the product of a gene linked to Hepatocellular Carcinoma. PROTEINS: Structure, Function and Bioinformatics, 55, 14-217. doi:10.1002/prot.20028
[8] Hori T., Kato S., Saeki M., DeMartino G. N., Slaughter C.A., Takeuchi J., Tohe A., and Tanaka K. (1998) cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome. Gene, 216, 113-122. doi:10.1016/S0378-1119(98)00309-6
[9] Higashitsuji H., Higashitsuji H., Itoh K., Sakurai T., Nagao, T., Sumitomo H., Masuda T., Dawson S., Shimada Y., Mayer R.J., and Fujita J. (2005) The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell, 8, 75-87. doi:10.1016/j.ccr.2005.06.006
[10] Li H., Fu X., Chen Y., Hong Y., Tan Y., Cao H., Wu M., and Wang H. (2005) Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology, 128, 2029-2041. doi:10.1053/j.gastro.2005.03.001.
[11] Nagao T., Higashitsuji H., Nonoguchi K., Sakurai T., Dawson S., Mayer R.J., Itoh K., and Fujita J. (2003) MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem, 278, 10668-10674. doi:10.1074/jbc.M206104200
[12] Sakurai T., Itoh K., Higashitsuji H., Nagao T., Nonoguchi K., Chiba, T., and Fujita J. (2004) A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem, 279, 15505-15514. doi:10.1074/jbc.M310437200
[13] Chothia, C. and Lesk, A. M. (1986)The relation between the divergence of sequence and structure in proteins. EMBO J., 5, 823-826. doi:10.1002/prot.22927/abstract.
[14] Eswar N., Marti-Renom M. A., Webb B., Madhusudhan M. S., Eramian D., Shen M., Pieper U., and Sali A, . Comparative Protein Structure Modeling With MODELLER. Current Protocols in Bioinformatics, John Wiley & Sons, Inc., Supplement 15, 5.6.1-5.6.30, 2006. doi:10.1002/0471140864.ps0209s50.
[15] Marti-Renom M.A., Stuart A., Fiser A., Sánchez R., Melo F., and Sali A. (2000) Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct,. 29, 291-325. PMID: 10940251 doi:10.1146/annurev.biophys.29.1.291
[16] Lipman D.J. and Pearson W.R., (1985) Rapid and sensitive protein similarity searches. Science 227, 1435– 1441. doi:10.1126/science.2983426
[17] Altschul S. F., Gish W., Miller W., Myers E.W., and Lipman D.J.(1990), Basic local alignment search tool. J Mol Biol, 215, 403–410. doi:10.1006/jmbi.1990.9999
[18] Bingding, H. and Schroeder M. (2006) LIGSITEcsc: predicting protein binding sites using the Connolly surface and degree of conservation, BMC structural Biology, 6, 19. doi:10.1186/1472-6807-6-1
[19] Schwede T., Diemand A., Guex N., and Peitsch M.C. (2000) Protein structure computing in the genomic era. Res Microbiol, 151, 107-112. doi:10.1016/S0923-2508(00)00121-2.
[20] Dawson, S., Higashitsuji, H., Wilkinson, A. J., Fujita, J. and John Mayer, R. (2006) Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends in Cell Biology. 16 (5). http://dx.doi.org/10.1016/j.tcb.2006.03.001

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.